Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Naoya, Emoto"'
Autor:
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Keizo Kato, Hiroshi Abe, Hirotaka Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Nonalcoholic fatty liver disease (NAFLD) is related to subclinical atherosclerosis. However, whether the severity of the disease (or which histopathological component) is associated with subclinical atherosclerosis remains controversial. Thi
Externí odkaz:
https://doaj.org/article/cce14aab56cd4efc9e98f6b71059a6f9
Autor:
Hiroshi Yamada, Fumitaka Okajima, Takeshi Onda, Shunji Fujimori, Naoya Emoto, Hitoshi Sugihara
Publikováno v:
BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves’ disease induced by ICIs. We report a case of new-onset Graves’ disease
Externí odkaz:
https://doaj.org/article/f01c3fef042244509d742eae0fc0fa09
Autor:
Tomoko Nagamine, Jaeduk Yoshimura Noh, Naoya Emoto, Takahito Kogai, Akira Hishinuma, Fumitaka Okajima, Hitoshi Sugihara
Publikováno v:
Thyroid Research, Vol 12, Iss 1, Pp 1-5 (2019)
Abstract Background Resistance to thyroid hormone (RTH) usually features a syndrome of inappropriate secretion of thyroid-stimulating hormone (SITSH) without suppression of the typical high thyroid hormone levels. However, some patients with RTH show
Externí odkaz:
https://doaj.org/article/cf87b809ebaf4401b709461282993686
Autor:
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 12 (2021)
Background: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM),
Externí odkaz:
https://doaj.org/article/41d7d403604345b8b5e39f5e1539d661
Autor:
Naoya Emoto, Rei Goto
Publikováno v:
Nihon Ika Daigaku Igakkai Zasshi. 18:379-388
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6204ea56c6aa1967876ebfa1bec0b50c
https://doi.org/10.1272/manms.18.379
https://doi.org/10.1272/manms.18.379
Autor:
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadamichi Kawano, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Chiaki Kawamoto, Tsutomu Hatori, Naoya Emoto, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0224184 (2019)
Although the presence of nonalcoholic fatty liver disease (NAFLD) is known to be related to subclinical atherosclerosis, the relationship between the severity of NAFLD and subclinical atherosclerosis is not clear. This study aimed to clarify the fact
Externí odkaz:
https://doaj.org/article/dad3abdfa6874df7b2b836661d2abfa5
Publikováno v:
Journal of Nippon Medical School. 89:196-202
Background The number of people diagnosed with dementia worldwide is set to increase significantly. While patients with dementia often have comorbidities, particularly diabetes, patients with type 2 diabetes mellitus (T2DM) have a high risk of cognit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3d545bbf0bcadbe30e7b20dbcedfd1
https://doi.org/10.1272/jnms.jnms.2022_89-215
https://doi.org/10.1272/jnms.jnms.2022_89-215
Autor:
Hitoshi Sugihara, Naoya Emoto, Fumitaka Okajima, Yuji Yamaguchi, Mikiko Okazaki-Hada, Rei Goto
Publikováno v:
Patient preference and adherence
Naoya Emoto,1â 3 Mikiko Okazaki-Hada,1 Yuji Yamaguchi,1 Fumitaka Okajima,1,2 Rei Goto,4 Hitoshi Sugihara1 1Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 2Department of Dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88caed35ad1c7ecd382247af88459428
http://europepmc.org/articles/PMC8434921
http://europepmc.org/articles/PMC8434921
Autor:
Okajima, Fumitaka, Sugihara, Hitoshi, Emoto, Naoya, Fumitaka, Okajima, Hitoshi, Sugihara, Naoya, Emoto
Publikováno v:
Journal of Nippon Medical School. 88:71-79
BACKGROUND Combination therapy with an alpha-glucosidase inhibitor or glinide plus a dipeptidyl peptidase-4 inhibitor is thought to be effective for glycemic control because of its effects on postprandial hyperglycemia. However, no studies have direc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6471c281311daafef518b804e24fd8
https://doi.org/10.1272/jnms.jnms.2021_88-205
https://doi.org/10.1272/jnms.jnms.2021_88-205
Autor:
Naoya Emoto, Hitoshi Sugihara, Fumitaka Okajima, Takeshi Onda, Hiroshi Yamada, Shunji Fujimori
Publikováno v:
BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-6 (2020)
BMC Endocrine Disorders
BMC Endocrine Disorders
Background Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves’ disease induced by ICIs. We report a case of new-onset Graves’ disease after th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46dedc9d2ace941fb8f2ef93f84e1e33
http://link.springer.com/article/10.1186/s12902-020-00613-5
http://link.springer.com/article/10.1186/s12902-020-00613-5